This study first demonstrated a novel mechanism—that ATD exerted antitumor potential through suppressing TGF-β1-promoted HepG2 hepatoblastoma cell progression, which involves blocking p38MAPK and Smad 2 signaling (Figure 9). Here, TGFB1 is linked to hepatoblastoma.